Point72 Asia Singapore Pte. Ltd. Purchases Shares of 105,105 Kezar Life Sciences, Inc. (NASDAQ:KZR)

Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 105,105 shares of the company’s stock, valued at approximately $63,000. Point72 Asia Singapore Pte. Ltd. owned about 0.14% of Kezar Life Sciences at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Ikarian Capital LLC increased its position in shares of Kezar Life Sciences by 1.8% during the first quarter. Ikarian Capital LLC now owns 868,992 shares of the company’s stock valued at $783,000 after acquiring an additional 15,601 shares during the last quarter. Fidelis Capital Partners LLC acquired a new stake in shares of Kezar Life Sciences during the first quarter valued at about $25,000. Vanguard Group Inc. increased its position in shares of Kezar Life Sciences by 1.0% during the first quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock valued at $2,790,000 after acquiring an additional 30,740 shares during the last quarter. Mackenzie Financial Corp acquired a new position in shares of Kezar Life Sciences in the second quarter valued at approximately $35,000. Finally, Acadian Asset Management LLC grew its holdings in shares of Kezar Life Sciences by 3.6% in the second quarter. Acadian Asset Management LLC now owns 1,855,194 shares of the company’s stock valued at $1,112,000 after purchasing an additional 64,356 shares in the last quarter. 67.90% of the stock is currently owned by institutional investors and hedge funds.

Kezar Life Sciences Trading Down 3.4 %

Shares of KZR stock opened at $0.80 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.58 and a current ratio of 9.58. The stock has a market capitalization of $58.06 million, a P/E ratio of -0.57 and a beta of 0.21. The company has a 50 day moving average price of $0.61 and a 200 day moving average price of $0.70. Kezar Life Sciences, Inc. has a fifty-two week low of $0.52 and a fifty-two week high of $1.14.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. Equities research analysts predict that Kezar Life Sciences, Inc. will post -1.2 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating on shares of Kezar Life Sciences in a report on Wednesday.

Kezar Life Sciences Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.